Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) EBT Margin (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of EBT Margin data on record, last reported at 12.54% in Q3 2025.

  • For Q3 2025, EBT Margin fell 886.0% year-over-year to 12.54%; the TTM value through Sep 2025 reached 10.49%, up 3148.0%, while the annual FY2024 figure was 7.78%, 530.0% down from the prior year.
  • EBT Margin reached 12.54% in Q3 2025 per PLX's latest filing, up from 4.22% in the prior quarter.
  • Across five years, EBT Margin topped out at 94.23% in Q4 2021 and bottomed at 176.89% in Q2 2021.
  • Average EBT Margin over 5 years is 24.29%, with a median of 25.15% recorded in 2022.
  • Peak YoY movement for EBT Margin: crashed -13871bps in 2021, then skyrocketed 11695bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 94.23% in 2021, then crashed by -140bps to 37.25% in 2022, then plummeted by -65bps to 61.28% in 2023, then soared by 166bps to 40.16% in 2024, then tumbled by -69bps to 12.54% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 12.54% in Q3 2025, 4.22% in Q2 2025, and 36.9% in Q1 2025.